T cell therapy to help prevent COVID-19 after transplant
Part of Infections, Lungs & breathing clinical trials.
This Phase 1 trial tests a donated immune-cell treatment (T cells) to help immunocompromised people fight or resist COVID-19 after they recently received a bone marrow or stem cell transplant. It aims to see if the treatment is safe and if it helps the body respond better to the virus.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re the right age: adults 18–79, or children 2–17, when you enroll
- You had a stem cell transplant 28 days to less than 4 months ago, and you’re at risk for COVID-19
- Your blood counts are recovering after transplant (ANC at least 500 for three checks; platelets and hemoglobin above minimums)
- Your body is stable enough for treatment (breathing room-air oxygen at least 92% for 7 days, and blood pressure/vitals meet thresholds)
- You haven’t had certain immune-blocking medicines or other cell therapies very recently before the infusion
- You do not currently have active COVID-19 infection, and you don’t have uncontrolled or worsening infections or unexplained fever
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding back certain immune cells after a stem cell transplant can help prevent serious viral or fungal infections. It's for children and young adults up to age 25 who need a transplant for a blood cancer or other curable disease.
This Phase 2 study gives you special “virus-targeting” immune cells (T-cells) to help your body control a current viral infection or virus that has come back (reactivated). It may help reduce the virus activity while you are immunocompromised, meaning your immune system is weaker than usual.
This early-phase study tests immune cells from a matched family donor (made to target the COVID-19 virus) to see if they can help people with mild-to-moderate COVID-19 who are hospitalized and at higher risk for getting sicker. It aims to check safety first and also look for signs of benefit.
This trial tests a treatment using specially grown T-cells (a type of immune cell) to fight certain viruses that won't go away with standard medicines. It is for people who have had a stem cell or organ transplant, or who have a weak immune system, and who are struggling with adenovirus, CMV, or EBV infections.
This trial tests a personalized immune cell treatment (CMV-specific T cells) for people whose CMV (a common herpes virus) persists or comes back after a stem cell transplant. It may help your immune system better control CMV when standard antiviral medicines aren’t fully working or can’t be used.
This trial tests virus-fighting immune cells (T-cells) made from a donor to treat stubborn CMV or adenovirus infections after a blood and bone marrow transplant. It may help clear the virus when standard antiviral medicines are not working.
Hear when a new SARS CoV 2 Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.